The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 14, 2020
Filed:
Dec. 28, 2018
Applicant:
Novira Therapeutics, Inc., Doylestown, PA (US);
Inventors:
Austin Chen, San Marcos, CA (US);
Yalda Bravo, San Diego, CA (US);
Nicholas Stock, Encinitas, CA (US);
Bijan Pedram, San Diego, CA (US);
Jason Jacintho, San Diego, CA (US);
Ryan C. Clark, San Diego, CA (US);
Assignee:
NOVIRA THERAPEUTICS, INC., Doylestown, PA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07C 323/53 (2006.01); C07C 323/22 (2006.01); C07C 323/23 (2006.01); C07C 323/62 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 295/084 (2006.01); C07D 295/155 (2006.01); C07D 295/192 (2006.01); C07D 307/10 (2006.01); C07D 307/16 (2006.01); C07D 309/04 (2006.01); C07D 309/08 (2006.01); C07D 487/10 (2006.01); A61K 31/5375 (2006.01); A61K 31/196 (2006.01); A61K 31/351 (2006.01); A61K 31/341 (2006.01); A61K 31/24 (2006.01); C07D 305/06 (2006.01); A61K 31/337 (2006.01); A61K 31/18 (2006.01); A61K 31/4453 (2006.01); A61K 31/495 (2006.01); A61K 31/397 (2006.01); A61K 45/06 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/44 (2006.01); A61K 31/4412 (2006.01); C07C 323/25 (2006.01); C07C 323/52 (2006.01); C07D 307/18 (2006.01);
U.S. Cl.
CPC ...
C07C 323/53 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/216 (2013.01); A61K 31/24 (2013.01); A61K 31/337 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/397 (2013.01); A61K 31/44 (2013.01); A61K 31/4412 (2013.01); A61K 31/4453 (2013.01); A61K 31/495 (2013.01); A61K 31/5375 (2013.01); A61K 45/06 (2013.01); C07C 323/22 (2013.01); C07C 323/25 (2013.01); C07C 323/52 (2013.01); C07C 323/62 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 295/084 (2013.01); C07D 295/155 (2013.01); C07D 295/192 (2013.01); C07D 305/06 (2013.01); C07D 307/10 (2013.01); C07D 307/16 (2013.01); C07D 307/18 (2013.01); C07D 309/04 (2013.01); C07D 309/08 (2013.01); C07D 487/10 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2601/18 (2017.05); C07C 2602/18 (2017.05); C07C 2602/20 (2017.05);
Abstract
The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.